PMGMU
Priveterra Acquisition Corp. [PMGMU] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PMGMU Stock Summary
In the News
Priveterra Acquisition says it will list on NYSE after AEON combination
Priveterra Acquisition said that following its planned business combination with AEON Biopharma the combined company will list on the New York Stock Exchange.
Priveterra Acquisition Corp. Receives Expected Notification from Nasdaq Related to Delayed Quarterly Report
FORT LAUDERDALE, Fla., June 04, 2021 (GLOBE NEWSWIRE) -- Priveterra Acquisition Corp. (the “Company”) today announced it received a notice on May 28, 2021 from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the “Quarterly Report”), the Company no longer complies with the continued listing requirements set forth in Nasdaq Listing Rule 5250(c)(1) (the “Rule”). The notice has no immediate impact on the listing of the Company's securities, which will continue to trade on the Nasdaq, subject to the Company's compliance with other applicable continued listing requirements.
Priveterra Acquisition Corp. Announces the Separate Trading of its Common Stock and Warrants, Commencing April 1, 2021
FORT LAUDERDALE, Fla., March 25, 2021 (GLOBE NEWSWIRE) -- Priveterra Acquisition Corp. (Nasdaq: PMGMU) (the “Company”) today announced that, commencing April 1, 2021, holders of the units sold in the Company's initial public offering may elect to separately trade shares of the Company's Class A common stock and warrants included in the units.
Priveterra Acquisition Corp. Announces Closing of $276 Million Initial Public Offering
FORT LAUDERDALE, Fla., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Priveterra Acquisition Corp. (Nasdaq: PMGMU) (the “Company”) today announced that it closed its initial public offering of 27,600,000 units. The offering was priced at $10.00 per unit, resulting in gross proceeds of $276,000,000.
PMGMU Financial details
PMGMU Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.23 | 0.17 | 0 | 0 | 0 | |
| Net income per share | 11.69 | -2.22 | -2.53 | 0 | 0 | |
| Operating cash flow per share | -3.02 | -0.64 | -1.29 | 0 | 0 | |
| Free cash flow per share | -3.14 | -0.64 | -1.3 | 0 | 0 | |
| Cash per share | 7.55 | 1.36 | 0.23 | 0 | 0 | |
| Book value per share | -4.54 | -14.08 | -10.68 | 0 | 0 | |
| Tangible book value per share | -4.45 | -13.74 | -10.18 | 0 | 0 | |
| Share holders equity per share | -4.54 | -14.08 | -10.68 | 0 | 0 | |
| Interest debt per share | 2.53 | 4.88 | 3.95 | 0 | 0 | |
| Market cap | 136.13M | 136.13M | 202.36M | 0 | 0 | |
| Enterprise value | 159.75M | 188.12M | 284.13M | 121.79M | -4.88M | |
| P/E ratio | 0.79 | -4.14 | -3.64 | 0 | 0 | |
| Price to sales ratio | 40.55 | 54.06 | 0 | 0 | 0 | |
| POCF ratio | -3.04 | -14.39 | -7.12 | 0 | 0 | |
| PFCF ratio | -2.93 | -14.39 | -7.07 | 0 | 0 | |
| P/B Ratio | -2.03 | -0.65 | -0.86 | 0 | 0 | |
| PTB ratio | -2.03 | -0.65 | -0.86 | 0 | 0 | |
| EV to sales | 47.59 | 74.71 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -3.17 | -8.5 | -35.91 | -2.52 | 0 | |
| EV to operating cash flow | -3.57 | -19.88 | -9.99 | -3.42 | 0 | |
| EV to free cash flow | -3.44 | -19.88 | -9.93 | -3.39 | 0 | |
| Earnings yield | 1.27 | -0.24 | -0.27 | 0 | 0 | |
| Free cash flow yield | -0.34 | -0.07 | -0.14 | 0 | 0 | |
| Debt to equity | -0.45 | -0.35 | -0.37 | -0.46 | 0 | |
| Debt to assets | 0.26 | 3.4 | 13.5 | 12.2 | 0.04 | |
| Net debt to EBITDA | -0.47 | -2.35 | -10.33 | -2.52 | 0 | |
| Current ratio | 6.41 | 4.85 | 0.25 | 0.12 | 0.48 | |
| Interest coverage | -7.22 | -1.09K | 0 | 0 | 0 | |
| Income quality | -0.28 | 0.29 | 0.51 | 0.68 | 0 | |
| Dividend Yield | 0.62 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.49 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 1.43 | 2.91 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.04 | 0 | 0.01 | 0.01 | 0 | |
| Capex to revenue | -0.5 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -1.35 | 0 | -56.67 | -4.5 | 0 | |
| Stock based compensation to revenue | 1.56 | 1.9 | 0 | 0 | 0 | |
| Graham number | 34.54 | 26.54 | 24.66 | 0 | 0 | |
| ROIC | 1.6 | 0.12 | 0.68 | 0.31 | 0 | |
| Return on tangible assets | 1.51 | -1.55 | -8.64 | -4.88 | 0 | |
| Graham Net | -4.61 | -13.81 | -10.24 | 0 | 0 | |
| Working capital | 94.65M | 16.18M | -15.65M | -72.74M | -6.83M | |
| Tangible asset value | -65.87M | -203.23M | -223.82M | -270.41M | -153.04M | |
| Net current asset value | -68.08M | -204.07M | -225.11M | -271.35M | -153.67M | |
| Invested capital | -0.45 | -0.35 | -0.37 | -0.46 | 0 | |
| Average receivables | 0 | 133.5K | 0 | 0 | 0 | |
| Average payables | 0 | 1.53M | 1.61M | 4.5M | 5.6M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 29.03 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 374.13K | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 12.57 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -2.58 | 0.16 | 0.24 | 0.18 | 0 | |
| Capex per share | -0.11 | 0 | -0.01 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2020-12-31 | 2021-06-30 | 2021-12-31 | 2022-12-31 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0 | 0 | 0 | 0 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | 0 | 0 | 0 | 0 | 0 | |
| Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value | 51.99M | 68.74M | 81.76M | 121.79M | -16.13M | |
| P/E ratio | 0 | 0 | 0 | 0 | 0 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
| P/B Ratio | 0 | 0 | 0 | 0 | 0 | |
| PTB ratio | 0 | 0 | 0 | 0 | 0 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 0 | 0 | 0 | -8.12 | 0 | |
| EV to operating cash flow | 0 | 0 | 0 | -14.41 | 0 | |
| EV to free cash flow | 0 | 0 | 0 | -14.39 | 0 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | -0.35 | -0.37 | -0.37 | -0.46 | 0 | |
| Debt to assets | 3.4 | 4.22 | 13.5 | 12.2 | 0 | |
| Net debt to EBITDA | 0 | 0 | 0 | -8.12 | 0 | |
| Current ratio | 4.85 | 1.97 | 0.25 | 0.12 | 1.19 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0 | 0 | 0 | 0.24 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | -0.28 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 0 | 0 | 0 | 0 | |
| ROIC | 0 | 0 | 0 | 0.1 | 0 | |
| Return on tangible assets | 0 | 0 | 0 | -3.21 | 0 | |
| Graham Net | 0 | 0 | 0 | 0 | 0 | |
| Working capital | 16.18M | 8.62M | -15.65M | -72.74M | 2.73M | |
| Tangible asset value | -203.23M | -207.66M | -223.82M | -270.41M | -121.74M | |
| Net current asset value | -204.07M | -209M | -225.11M | -271.35M | -122.45M | |
| Invested capital | -0.35 | -0.37 | -0.37 | -0.46 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0 | 0 | 0 | 0.12 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
PMGMU Frequently Asked Questions
What is Priveterra Acquisition Corp. stock symbol ?
Priveterra Acquisition Corp. is a US stock , located in Fort lauderdale of Fl and trading under the symbol PMGMU
What is Priveterra Acquisition Corp. stock quote today ?
Priveterra Acquisition Corp. stock price is $10.99 today.
Is Priveterra Acquisition Corp. stock public?
Yes, Priveterra Acquisition Corp. is a publicly traded company.
Company Profile
- Volume Average 67
- CEO Mr. Robert J. Palmisano
- Headquarters Fort Lauderdale,FL,US
- IPO Date 2021-02-09
Priveterra Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to acquire companies in the medical technology sector. The company was incorporated in 2020 and is based in Fort Lauderdale, Florida.
